A structural biology view of target drugability
Ursula Egner, Roman Christian Hillig · Expert Opinion on Drug Discovery · 2008
BACKGROUND: With long and costly drug development times there is a need in the pharmaceutical industry to prioritize targets early in the drug discovery process. One of the possible criteria is 'protein drugability', a term with multiple understandings in the literature. Among others, it is the likelihood of finding a selective, low-molecular weight molecule that binds with high affinity to the target. OBJECTIVE: Which methods are available for drugability prediction? What can be achieved by such predictions and how can they influence the target prioritization process? METHODS: The main focus is on sequence- and structure-related computational methods for drugability prediction, giving an overview on their background as well as their bias and limitations with an emphasis on the structural biology point of view. RESULTS/CONCLUSION: Structural drugability assessment presents one criterion for prioritization of a target portfolio by enabling classification of targets into low, average, or high drugability.